eFFECTOR Therapeutics, Inc. Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2024-03-31..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2024-03-31..
Cash and securities
Overview →Financial period ending 2024-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2024-03-31. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2024-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 15.51M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2024-03-31 | (m) | (m) | $15.51M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $14.88M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $5.39M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $14.71M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $10.31M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $8.71M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $11.90M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $16.35M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $17.66M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $49.70M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $54.77M | (m) | (m) |
| 2021-07-31 | (m) | (m) | $10.90M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $10.88M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $16.77M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $15.22M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $24.34M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $3.43M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.